IP Library Granted Patent US 10,179,120
Granted Patent B2
US 10,179,120 · App. 15/110,003 · Granted Jan 15, 2019

Dosage regimen of ferric trimaltol

Inventors: Christian Schweiger (Wollerau, CH); Carl Andrew Sterritt (Wollerau, CH); Julian David Howell (Wollerau, CH)
Assignee: Iron Therapeutics Holdings AG
A61K31/351A61K9/48A61K33/26A61K47/02A61K47/12A61K47/20A61K47/26A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,120
App. No.
15/110,003
Granted
Jan 15, 2019
Kind
B2
Abstract

The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.

Claims (17)

1. A method for the treatment of iron deficiency with or without anaemia in a patient, comprising administering orally to the patient ferric trimaltol as a 30 mg elemental iron preparation on an empty stomach twice daily, wherein the percentage of ferric trimaltol is at least 60% of the combined weight of ferric trimaltol and excipients, wherein iron deficiency with or without anaemia is a result of, or associated with active inflammatory disease or active acute/chronic inflammation.

2. The method of claim 1 wherein iron deficiency is iron deficiency with anaemia in inflammatory bowel disease.

3. The method of claim 2 wherein the inflammatory bowel disease is Crohn's disease.

4. The method of claim 2 wherein the inflammatory bowel disease is ulcerative colitis.

5. The method of claim 1 wherein said ferric trimaltol 30 mg elemental iron preparation is administered once prior to breakfast and once prior to sleep.

6. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation is administered for up to a twelve week period.

7. The method of claim 6 , further comprising administering orally after the twelve week period to the patient ferric trimaltol as a 30 mg-120 mg elemental iron preparation once daily, or once every two, three, four, five, six or seven days.

8. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation is administered indefinitely as a maintenance dose.

9. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation is a size 1 capsule.

10. The method of claim 1 wherein the ferric trimaltol 30 mg elemental iron preparation comprises:

231.5 mg ferric trimaltol,

91.5 mg lactose monohydrate,

3.0 mg sodium lauryl sulphate,

9.0 mg crospovidone,

0.6 mg colloidal silicon dioxide, and

3.0 mg magnesium stearate.

11. A method for the treatment of iron deficiency with or without anaemia in a patient, comprising administering orally to the patient ferric trimaltol as a 30 mg elemental iron size 1 capsule on an empty stomach twice daily, once prior to breakfast and once prior to sleep for up to a twelve week period, wherein the percentage of ferric trimaltol is at least 60% of the combined weight of ferric trimaltol and excipients, wherein iron deficiency with or without anaemia is a result of, or associated with active inflammatory disease or active acute/chronic inflammation.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF CONVEYING PARTY FROM IRON THERAPEUTICS AG TO IRON THERAPEUTICS HOLDINGS AG PREVIOUSLY RECORDED ON REEL 50419 FRAME 95. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 3, 2025
From: IRON THERAPEUTICS HOLDINGS AG
To: SHIELD TX (UK) LTD.
Reel/Frame 073133/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2025
From: IRON THERAPEUTICS HOLDINGS AG
To: SHIELD TX (UK) LIMITED
Reel/Frame 072147/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2024
From: STERRITT, CARL ANDREW; SCHWEIGER, CHRISTIAN; HOWELL, JULIAN DAVID
To: IRON THERAPEUTICS (UK) LIMITED
Reel/Frame 067502/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2024
From: IRON THERAPEUTICS (UK) LIMITED
To: IRON THERAPEUTICS HOLDINGS AG
Reel/Frame 067502/0758 →
SECURITY INTEREST Recorded Oct 4, 2023
From: SHIELD TX (UK) LIMITED
To: SWK FUNDING LLC
Reel/Frame 065126/0142 →
RELEASE OF SECURITY INTEREST Recorded Oct 4, 2023
From: AOP HEALTH INTERNATIONAL MANAGEMENT AG
To: SHIELD TX (UK) LIMITED
Reel/Frame 065125/0610 →
SECURITY INTEREST Recorded Jan 4, 2023
From: AOP HEALTH INTERNATIONAL MANAGEMENT
To: SHIELD TX (UK) LIMITED
Reel/Frame 062273/0488 →
SECURITY INTEREST Recorded Aug 1, 2022
From: SHIELD TX (UK) LIMITED
To: AOP HEALTH INTERNATIONAL MANAGEMENT AG
Reel/Frame 060684/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: IRON THERAPEUTICS AG
To: SHIELD TX (UK) LTD.
Reel/Frame 050419/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2016
From: SCHWEIGER, CHRISTIAN; STERRITT, CARL ANDREW; HOWELL, JULIAN DAVID
To: IRON THERAPEUTICS HOLDINGS AG
Reel/Frame 040667/0883 →
Priority Claims (2)
GB 1400171.3 · Jan 6, 2014 · national
GB 1418708.2 · Oct 21, 2014 · national
Continuity (1)
Related Publication 20160324822A1 · Nov 10, 2016